Drugs / BI 3804379
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06575400 | Sep 2024 → Feb 2028 expected | metabolic dysfunction-associated steatohepatitis | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3804379 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06575400 ↗ |
| Route | Subcutaneous | “Single and Multiple Rising Subcutaneous Doses” NCT06575400 ↗ |